Imatinib, a KIT/PDGFRA tyrosine kinase inhibitor (TKI), is an effective first-line therapy for patients with advanced GIST; however, most patients ultimately develop disease progression due to secondary resistance mutations4–10. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.